Bifogade filer
PR CEO EN 230526 FINAL
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).
“The appointments of Peter Selin as CEO and Thomas Olin as CSO are central to Kancera’s strategy and plan for succession and have been initiated by Kancera’s current CEO and board to add momentum in our development and commercialization activities. We are confident that Peter’s expertise and experience in licensing and commercialization through partnerships is very suitable to lead the company in this exciting phase. We are at the same time very happy that Thomas Olin can increase his focus on research and development and that he will remain as a member of the board. The collaboration between Peter and Thomas has worked very well since Peter joined the company and the board is convinced that this will continue and that the new constellation will be synergistic and strengthen Kancera”, says Erik Nerpin, chairman of the board of Kancera AB.
Peter Selin, who today holds the position as Executive Vice President Corporate Development and Finance, has more than 20 years of experience in development, licensing and commercialization of specialty pharma products. Peter has previously held senior business development and operational positions, e.g. as Vice President Corporate Development at Sobi and Chief Business Officer at Vivesto. In his previous roles, Peter has executed a number of licensing transactions and in his new role as CEO he will continue to be responsible for licensing activities and strategic partnerships.
About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.
For further information:
Erik Nerpin
Chairman of the board, Kancera AB
Tel: +46 (0)70-620 7359
Visit Kancera’s web page: https://www.kancera.com/en